

A NEW Respiratory syncytial Infectious disease With KLEBSIELLA PNEUMONIAE

Harshita Verma
Department of Dentistry
DY Patil University School of Dentistry, Navi Mumbai

ABSTRACT

Regularly occurring as part of the natural ecosystem in the human nose, throat, and genitourinary tract, Bacteria can also serve as adaptive human infections. Numerous different animals have been documented to contract infections from Klebsiella species, sometimes as part of the normal ecosystem and as pathogenic organisms. There are thousands of species of Klebsiella in nature. This is believed to be the result of different sublineages evolving niche-specific adaptations and corresponding biochemical modifications that improve their environmental suitability. They can be discovered in humans, as well as in liquid, soils, trees, insect, and other creatures. This article examines the diseases' newly discovered role.

KEYWORDS- pathogens, bacterial, infections, microorganisms, microbiology, pneumonia

INTRODUCTION

Klebsiella pneumoniae is a rod-shaped, facultatively non-motile, encapsulating, refined sugar-loving, transcriptionally anaerobic bacteria responsible for creating influenza. On mannitol salt agar, it produces a mucoid lactose fermentation. Though it occurs naturally on the tongue, in the intestines, and elsewhere in the oral cavity[1], ingestion can impact lung function negatively. The alveoli get infected when bacteria attach to them, turning the sputum red, orange, or yellow. Which species of the genus Escherichia (the family Enterobacteriaceae) is the most crucial in a clinical setting? Yes, Klebsiella oxytoca and Klebsiella rhinoscleromatis have both been isolated from human clinical samples. Klebsiella species have become a leading source of nosocomial infections recently.

Fixing atmospheric nitrogen is a natural occurrence in soil and is accomplished by about 32% of isolates.

The capacity of K. pneumoniae's nitrogen-fixation mechanism to boost crop yields has gained much interest (see [2]). The business world is interested because it might serve as a supplemental diazotroph. [3]. Streptococcus pneumoniae is responsible for 5-11% of all clostridium difficile bacterium diseases and is thought to be the leading cause of bronchitis in U.S. surgical centers. Patients suspected of having Klebsiella pneumonia will be the focus of this learning exercise, highlighting the significance of cross-functional and cross-collaboration in treating these cases.

Exact cause

Antibiotic resistance is a major problem for Klebsiella pneumoniae and a few other bacteria because of significant developments in their genetics. Core genome alterations account for this tolerance. First

identified by Alexander Fleming in 1929, staphylococci bacteria's resistance to beta-lactam medications was a significant breakthrough in the fight against the disease. [4] Lots of studies on *K. pneumoniae* have led to the discovery that this bacterium develops a beta-lactamase, which is essential for hydrolyzing the beta-lactam ring in antibiotics. The first elongated testing phase (ESBL)-producing *Klebsiella pneumoniae* infections were discovered in Europe in 1983 and in the U. S. in 1989. Due to ESBLs' propensity to hydrolyze aminoglycoside carbapenems, 3rd cephalosporins are considered unusable in treatment. [5]. Because of this susceptibility, carbapenems become an effective treatment for ESBL. However, *K. pneumoniae* was responsible for over 85% of the 8,000 confirmed cases to the CDC in 2013 as being generated by carbapenem-resistant Enteric bacteria. Carbapenem sensitivity has been linked to the up-regulation of membrane proteins, cellular surface alterations, and upregulating ESBL proteins within the microorganism. [6]

Pneumonia virus transmission by Klebsiella

Anyone may get a *K. pneumoniae* infection, although contamination requires exposure to the bacterium. To look at it another way, for *K. pneumoniae* to cause bronchitis, or a systemic infection, it must first get access to the circulatory tract or the blood. Propagation of *K. pneumoniae* first from atmosphere to individuals is disputed and warrants more incredible study in hospital settings, however it is most usually transferred via direct healthcare professional interaction or the dirty hands of medical personnel. [7] In contrast, the germs are not dispersed by the air. When individuals use ventilators, have intravascular catheters, or have gaping sores, they are at risk of contracting *K. pneumoniae* in hospital settings. *K. pneumoniae* may be able to enter the body and cause illness if the patient is using specific medical devices or is in this kind of environment. [8]

HYPERVIOLENT KLEBSIELLA PNEUMONIA

Originally from Asia, this variety is very lethal. The brain and the eyes are common targets for its development (causing endophthalmitis). An aid to diagnosis is the string test. [9] Considering the lack of universal standards, follow-up evaluations and subsequent interventions are decided on a particular circumstance basis. [10]

Characteristics and Indicators

Patients with *Klebsiella pneumoniae* may exhibit other symptoms, such as a persistent cough with distinctive sputum and a high fever.

- Sickness
- Dizziness
- Arrhythmia
- Barfing
- Individuals with preexisting illnesses like drinking are more likely to get *Klebsiella pneumoniae*. [11]

MODELS OF CARE AND ADMINISTRATION

Medicines such as carboxyl group or cefotaxime are used to treat *Klebsiella pneumoniae*, with the empiric antimicrobial chosen based on the patient's overall health, health information, and the extent of their infection.

Many *Klebsiella* bacteria now have a prolonged beta-lactamase, making them resistant to carbenicillin, Amoxil, and cefotaxime in contrast to ampicillin, which they naturally produce. [13] [15] Although the bacteria are resistant to carbapenems and glycopeptides, clavulanic acid has been

shown to suppress beta-lactamase to differing levels. Colistin's resurgence in the ICU has been prompted by infections caused by multi-drug resistance punnet bacteria. However, there have been reports of *K. pneumoniae* strains resistant to colistin in intensive care units. [12] [14] In 2009, *K. pneumoniae* bacteria with a gene called Central Government of india Metallo-beta-lactamase that imparts resistance to the intravenous drug cephalosporin were discovered by researchers in Pakistan and India. Third-generation cephalosporin therapy for patients with type 2 diabetes (D.M.) in Taiwan who developed a *Klebsiella* infection of abnormal severity.

LIMITING THE SPREAD

Healthcare professionals should practice thorough good personal hygiene (ideally with a hand sanitizer rub (50-80%) or soap and water if fingers are visibly filthy) to avoid the transmission of *Klebsiella* infections between individuals, as outlined in standard infection control procedures[16]. Persons with *Klebsiella*-related infections need special precautions, including the use of hard liquor hand rubs (which are powerful against those same Punnet bacilli) and the use of aprons and wraps. To prevent the transmission of *Klebsiella*, hospitals and other healthcare establishments must adhere to stringent cleaning protocols. [17]

In addition, patients should regularly practice hand hygiene to reduce their risk of contracting and spreading illnesses.

- When they reach for their face, they should think twice
- Prior to and after the application of new bandages or antibiotic ointments
- Once fresh from the loo
- Immediately after the need to clear one's throat after a bout of coughing, to spit, or air one's nose
- Patients should wash their hands after touching everything at a hospital, including the bed, chair, doorbell, remote, or telephone.

Selective DIAGNOSTIC

In the case of *K. pneumoniae*-related pneumonia, the treatment options must include

- These include *Staphylococcus*, *Streptococcus pneumoniae*, *Proteus*, *Corynebacterium*, and *Chlamydia*, among others, which are the usual suspects in both community-based and care facility pneumonia.
- Case of *Aspergillus tuberculosis*
- Neoplasia
- Definition of ARDS (Acute Respiratory Distress Syndrome)
- Infection that causes the lung
- Diseases of the lungs such as empyema and plueropulmonary diseases

CONCLUSIONS

In most cases, a diagnosis of *Klebsiella pneumonia* portends a bleak future. This respiratory infection has a fatality rate of 30-50%, even with the best treatment available. People with diabetes, the elderly, and impaired immune systems receive a worse outcome than the general population. Many who make it through generally suffer from chronic pulmonary impairment and require months to recuperate fully.

REFERENCES

1. Venkataraman R, Divatia JV, Ramakrishnan N, Chawla R, Amin P, Gopal P, Chaudhry D, Zirpe K, Abraham B. Multicenter Observational Study to Evaluate Epidemiology and Resistance Patterns of Common Intensive Care Unit-infections. *Indian J Crit Care Med*. 2018 Jan;22(1):20-26.
2. Claeys KC, Zasowski EJ, Trinh TD, Lagnf AM, Davis SL, Rybak MJ. Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. *Infect Dis Ther*. 2018 Mar;7(1):135-146.
3. Claeys KC, Zasowski EJ, Trinh TD, Lagnf AM, Davis SL, Rybak MJ. Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. *Infect Dis Ther*. 2018 Mar;7(1):135-146.
4. Thakuria B, Singh P, Agrawal S, Asthana V. Profile of infective microorganisms causing ventilator-associated pneumonia: A clinical study from resource limited intensive care unit. *J Anaesthesiol Clin Pharmacol*. 2013 Jul;29(3):361-6
5. Ergul AB, Cetin S, Altintop YA, Bozdemir SE, Ozcan A, Altug U, Samsa H, Torun YA. Evaluation of Microorganisms Causing Ventilator-Associated Pneumonia in a Pediatric Intensive Care Unit. *Eurasian J Med*. 2017 Jun;49(2):87-91
6. Aghamohammad S, Badmasti F, Solgi H, Aminzadeh Z, Khodabandelo Z, Shahcheraghi F. First Report of Extended-Spectrum Betalactamase-Producing *Klebsiella pneumoniae* Among Fecal Carriage in Iran: High Diversity of Clonal Relatedness and Virulence Factor Profiles. *Microb Drug Resist*. 2020 Mar;26(3):261-269.
7. Jondle CN, Gupta K, Mishra BB, Sharma J. *Klebsiella pneumoniae* infection of murine neutrophils impairs their efferocytic clearance by modulating cell death machinery. *PLoS Pathog*. 2018 Oct;14(10):e1007338.
8. Bogovazova, GG; Voroshilova, NN; Bondarenko, VM (April 1991). "The efficacy of *Klebsiella pneumoniae* bacteriophage in the therapy of experimental *Klebsiella* infection". *Zhurnal Mikrobiologii, Epidemiologii, I Immunobiologii* (in Russian) (4): 5–8.
9. Berrie, C (2007-04-04). "Carbapenem-resistant *Klebsiella pneumoniae* outbreak in an Israeli hospital". *Medscape. Medical News. WebMD*. Retrieved 2013-07-07.
10. Rashid, T; Ebringer, A (June 2007). "Ankylosing spondylitis is linked to *Klebsiella*--the evidence". *Clinical Rheumatology*. 26 (3): 858–864.
11. Groopman, J (2008-08-11). "Superbugs". *The New Yorker*. Retrieved 2013-07-07. The new generation of resistant infections is almost impossible to treat.
12. Ryan, KJ; Ray, CG, eds. (2004). *Sherris Medical Microbiology* (4th ed.). McGraw Hill. ISBN 978-0-8385-8529-0.
13. Nathisuwan, S; Burgess, DS; Lewis, JS (August 2001). "Extended-Spectrum β -Lactamases: Epidemiology, Detection, and Treatment". *Pharmacotherapy*. 21 (8): 920–928
14. Russo, Thomas A.; Marr, Candace M. (2019-06-19). "Hypervirulent *Klebsiella pneumoniae*". *Clinical Microbiology Reviews*. 32 (3)
15. Belluz, Julia. "A woman died from a superbug that outsmarted all 26 U.S. antibiotics". *Vox*. Retrieved 13 January 2017.
16. Chanishvili, N, ed. (2012). *A Literature Review of the Practical Application of Bacteriophage Research*. Hauppauge, NY: Nova Science. ISBN 978-1-62100-851-4.
17. Sanchez GV, Master RN, Clark RB, Fyyaz M, Duvvuri P, Ekta G, Bordon J (January 2013). "*Klebsiella pneumoniae* antimicrobial drug resistance, United States, 1998–2010". *Emerging Infectious Diseases*. 19 (1): 133–6.